Since its founding in 1983, the Columbus CCOP, now known as the Columbus NCORP, has been dedicated to providing high quality cancer care options in Central and Southeast Ohio as well as advancing cancer research through cancer research trials. The Columbus NCORP has grown in that time to encompass 20 affiliates and sub-affiliates, with 100 doctors serving as investigators. The NCORP serves a wide variety of populations, from urban areas to rural Appalachia. Over the six years comprising the next grant period, the NCORP plans to continue to grow in that capacity, improving its ability to participate in, assist with the design of, and successfully implement a wide range of cancer research trials, including treatment, cancer control, screening/surveillance, side effect prevention/management, and cancer care delivery research studies. In all areas the NCORP has been successful and plans to continue to grow in its ability to investigate health disparities in its region and increase participation in cancer research by underserved communities including minority populations, rural communities and those in Appalachian areas. Cancer care delivery research has been and continues to be a key component of this goal, as is continuing to improve care practices throughout the consortium. Close collaboration between NCORP affiliate institutions, non-oncology specialists, primary care physicians and community organizations is key to this goal. The Columbus NCORP plans to continue to pursue the cutting edge of cancer research through targeted and genomic therapies, while simultaneously seeking out and implementing trials that are directly applicable to those cancers with the highest incidence rate in our region: breast, colon and lung cancers. Over the past five years as an NCORP, and over the preceding 30 years as the Columbus CCOP, these areas have been a high priority and will continue to be as we aggressively pursue treatments that will advance the science of cancer care and best serve our local communities. The unique challenges facing Central and Southeast Ohio in these areas position the Columbus NCORP to make real and lasting contributions to cancer research, and the lessons learned here are widely applicable to regions across the country.

Public Health Relevance

The Columbus Community Clinical Oncology Program has been serving Central Ohio for 35 years and has been participating in the NCI Community Oncology Research Program since its inception. During that time, the Columbus CCOP has excelled in delivering cancer care and access to clinical studies to a wide variety of populations ? from major urban areas to rural Appalachia. The Columbus CCOP is firmly committed to the idea that cancer therapy and clinical trials are mutually supportive, and looks forward to continuing to work and grow as an NCORP community site.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
2UG1CA189954-06
Application #
9774587
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Russo, Sandra
Project Start
2014-08-01
Project End
2025-07-31
Budget Start
2019-08-09
Budget End
2020-07-31
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Columbus Community Clinical Oncology Prg
Department
Type
DUNS #
140098778
City
Columbus
State
OH
Country
United States
Zip Code
43215
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Meropol, Neal J; Feng, Yang; Grem, Jean L et al. (2018) Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203). Cancer 124:688-697
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Wagner, Lynne I; Zhao, Fengmin; Goss, Paul E et al. (2018) Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG Breast Cancer Res Treat 169:537-548
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952

Showing the most recent 10 out of 17 publications